Home » Stocks » Advanz Pharma

Advanz Pharma Corporation Ltd. (CXRXF)

Stock Price: $4.00 USD 0.00 (0.00%)
Updated Sep 18, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 195.65M
Revenue (ttm) 503.46M
Net Income (ttm) -179.03M
Shares Out 48.91M
EPS (ttm) -3.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 18, 2020
Last Price $4.00
Previous Close $4.00
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 3.98 - 4.10
Day's Volume 0
52-Week Range 2.13 - 19.14

More Stats

Market Cap 195.65M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 48.91M
Float n/a
EPS (basic) n/a
EPS (diluted) -3.66
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6,759
Short Ratio 10.40
Short % of Float 4.61%
Beta 0.10
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.39
PB Ratio 11.64
Revenue 503.46M
Operating Income n/a
Net Income -179.03M
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share 0.00
Gross Margin 66.90%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA 1.41%
ROE -577.12%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$15.50*
Low
15.5
Current: $4.00
High
15.5
Target: 15.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name Advanz Pharma Corporation Ltd.
Country United Kingdom
Employees 429
CEO Graeme Neville Duncan

Stock Information

Ticker Symbol CXRXF
Stock Exchange US OTC
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier OTCMKTS: CXRXF

Description

ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates in two segments, ADVANZ PHARMA International and ADVANZ PHARMA North America. The ADVANZ PHARMA International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye; Zapain, a combination of codeine phosphate and paracetamol for severe pain reliefs, such as back pain, toothache, severe sprains and strains, and pain after operations. The ADVANZ PHARMA North America segment provides Donnatal, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. The company sells its products through direct sales and local distribution relationships. The company was formerly known as Concordia International Corp. and changed its name to ADVANZ PHARMA Corp. in November 2018. ADVANZ PHARMA Corp. is headquartered in London, the United Kingdom.